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http://www.translational-medicine.com/content/11/1/291RESEARCH Open AccessPhase I/II clinical trial using HLA-A24-restricted
peptide vaccine derived from KIF20A for patients
with advanced pancreatic cancer
Shingo Asahara1*, Kazuyoshi Takeda2, Kenji Yamao3, Hiroyuki Maguchi4 and Hiroki Yamaue5Abstract
Background: We previously developed an immunotherapy treatment utilizing a cancer vaccine reagent KIF20A-66
in order to treat pancreatic cancer. KIF20A-66 is HLA-A24-restricted epitope peptide derived from KIF20A, a member
of kinesin super family protein 20A that is significantly transactivated in pancreatic cancer. In this report, we further
demonstrated non-randomized, open-label, single centered phase I/II clinical trial of immunotherapy using the
KIF20A-66 peptide for the patients with advanced pancreatic cancer.
Methods: Vaccination was performed to the patients with metastatic pancreatic cancer, in whom gemcitabine-based
therapy had failed. In phase I study, KIF20A-66 peptide was subcutaneously injected weekly in a dose-escalation manner
(doses of 1.0 and 3.0 mg/body, 6 patients/1 cohort). After safety was assessed, phase II study was conducted using
3.0 mg of KIF20A-66 peptide.
Results: KIF20A-66 peptide vaccination was well tolerated in the doses we examined and tumor responses after
1 month of the treatment were evaluated. Among 29 patients who completed one course of the treatment at least,
stable disease (SD) was found in 21 cases, while progressive disease (PD) was found in 8 cases, indicating that the
disease control rate was 72%. Objective tumor shrinkage was observed in 8 cases, including 1 case of complete
response (CR). The median survival time (MST) and progression free survival time (PFS) were 142 days and 56 days,
respectively. These results clearly demonstrate that overall survival of the patients was significantly prolonged,
compared to the historical controls of 9 cases with unmatched HLA in the same hospital (MST: 83 days), as well
as 81 cases in our and other hospitals (MST: 63 days).
Conclusion: The patients vaccinated with KIF20A-66 peptide had better prognosis than the control group with best
supportive care (BSC). Thus, we concluded that KIF20A-66 vaccination is significantly effective as an immunotherapy
against advanced pancreatic cancer. KIF20A-66 peptide was well tolerable in the dose of either 1.0 mg or 3.0 mg/body,
and effectively induced peptide-specific response of cytotoxic T lymphocyte (CTL). Further clinical study using this
peptide is a promising approach for advanced pancreatic cancer to achieve high potential benefit for better prognosis.
Clinical trial registration: UMIN-CTR, number UMIN000004919
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Pancreatic cancer remains one of the most challenging
conditions to treat, due to extremely poor prognosis
with the overall five-year survival of less than 10% [1-3].
During the last decades, gemcitabine has been the
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reproduction in any medium, provided the orpancreatic cancer [4,5]. Regarding combination chemo-
therapy, several phase III trials of gemcitabine-based
multi-drug regimens have been attempted, whereas
significant improvement in survival has not been
observed [6-14]. Although TS-1, a prodrug of 5-FU,
has been employed as a major alternative approach in
a variety of solid tumors, the single-agent treatment of
TS-1 yielded non-inferiority result against the gemcitabine
treatment [15]. After all, once pancreatic cancer becamel Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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treatment for the patients. Hence, novel strategy providing
better survival benefit is urgently required, in particular,
for the patients with advanced pancreatic cancer.
Cancer immunotherapy is a promising approach to fight
against cancer, and thus we have conducted research and
development of peptide vaccines targeting tumor-specific
antigens [16-19]. Briefly, we identified dozens of cancer-
testis or oncofetal proteins from more than 1,000 clinical
cancer tissues using cDNA microarray including 32,000
genes or ESTs [20]. Utilizing the result of this genome-
wide expression profile analysis, we tried to establish an
epitope peptide derived from the tumor-associated antigen
mentioned above, which is applicable for cancer peptide
vaccination [21,22]. KIF20A, kinesin family member 20A,
is one of the candidates of such target antigen, as it was
up-regulated in the majority of pancreatic cancer [23].
Therefore, we developed an epitope peptide, namely
KIF20A-66, restricted to HLA-A*2402 that is the most
common HLA-A allele in a Japanese population [24].
We here report the results of a phase I/II clinical trial
using KIF20A-66 mono peptide as cancer immunotherapy
for the patients with advanced pancreatic cancer.
Methods
Patient eligibility
Patients with unresectable or metastatic pancreatic cancer,
who were resistant to gemcitabine and TS-1 treatments or
unable to continue the treatment of gemcitabine or TS-1
because of severe adverse events, were enrolled in this trial
from March 2009 to February 2010 at Chiba Tokushukai
Hospital. The eligibility criteria are as follows: unresectable
pancreatic cancer with metastatic, recurrent and/or locally
advanced disease based on diagnostic imaging using
computed tomography (CT) and histological examinations.
Other entry criteria included the HLA-A*2402-positive
status, an Eastern Cooperative Oncology Group (ECOG)
performance status of 0–2, age of 20–85 years, life
expectancy of at least 2 months, adequate respiratory,
and liver and kidney functions for vaccination treatment.
The exclusion criteria are as follows: pregnancy or lac-
tation, active infection, other active malignancy, non-
recovered injury, and treatment with immunosuppressive
agents or steroid. Written informed consent was obtained
from each individual patient, and the study was approved
by Tokushukai Group Ethical Committee. The study
was registered at University Hospital Medical Information
Network (UMIN) Center with the Clinical Trial Regis-
tration number UMIN000004919.
Control group
Clinical data used as the control group (BSC, multi-
center, n = 81) in this study were obtained from our and
other hospitals where written informed consent wasobtained at each institution. Clinical information of each
patient utilized in our statistical analysis includes age at
diagnosis, sex, performance status at the endpoint of
the Standard Chemotherapy, treatment status at primary
lesion, median survival time, and mean survival time. This
study was approved by the institutional review board at
each institution.
Study design and end points
This study is a non-randomized, open-label phase I/II
clinical trial with dose escalation of KIF20A-66 peptide
mono-therapy. The primary end point of phase I part
was safety of peptide vaccination and tolerance for
phase II part. The primary end point of phase II part
was antitumor effects assessed by CT scan in accordance
with the Response Evaluation Criteria in Solid Tumors
(RECIST) criteria version 1.1. The secondary end points
were overall survival (OS), progression free survival (PFS),
immunological responses assessed by CTL induction
specific to the KIF20A-66 peptide and the injection site
reactions (ISRs). In phase II part, the information of 9
patients with best supportive care in the Chiba Tokushukai
Hospital from January 2007 to January 2009 was used
as a historical control.
Treatment protocol
After emulsified with Incomplete Freund’s adjuvant
(Montanide ISA51VG, SEPPIC, France), KIF20A-66
peptide in the amount of 1.0 or 3.0 mg/body was sub-
cutaneously administered on days 1, 8, 15 and 22 in a
28 days-treatment cycle. After two cycles of the vaccination,
the peptide was administrated once in every two weeks
until tumor progression was observed in the patient.
Toxicity assessment
The toxicity was assessed based on the Common
Terminology Criteria for Adverse Events version 3.0
(CTCAE v3.0).
Peptides
The KIF20A-66 peptide (KVYLRVRPLL) was synthesized
and its quality was analyzed by American Peptide
Company Inc. (Sunnyvale, CA). The epitope peptide
derived from HIV-Env peptide (RYLRDQQLL), restricted
to HLA-A*2402, was used as a control to evaluate
CTL response.
Enzyme-linked immunospot (ELISPOT) assay
To evaluate the peptide-specific CTL response, ELISPOT
assay was performed after in vitro sensitization [16].
Briefly, frozen Peripheral Blood Mononuclear Cells (PBMC)
derived from the same patient were thawed, cultured
with respective peptide and IL-2 (Novartis, Emeryville,
CA) (IVS), and harvested after two weeks. Followed by
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utilizing HLA-A*2402-positive TISI cells (IHWG Cell and
Gene Bank, Seattle, WA) stimulated by either vaccinated
peptide or HIV-Env peptide (as control). Reaction in a
MultiScreen-IP 96-plate (Millipore, Bedford, MA) was
measured by an automated ELISPOT reader, Immuno-
SPOT S4 (Cellular Technology Ltd, Cleveland, OH)
with ImmunoSpot Professional Software Version 5.0
(Cellular Technology Ltd). All ELISPOT assays were
performed in triplicate. The number of peptide-specific
spots was calculated by subtracting the number of the
spots of control cells from that of the cells stimulated by
vaccinated peptide. The peptide-specific T cell response
was classified into four grades (−, +, ++, and +++), ac-
cording to the algorithm flow chart described in our
previous report (+++ : the content rate of CTL is more
than 0.2% , ++ : 0.02 - 0.2%, + : 0.01 - 0.02%, –: less than
0.01%) [25]. Sensitivity of ELISPOT assay was estimated
as approximate average level utilizing proficiency panels
conducted by Cancer Immunotherapy Consortium (CIC)
in 2009 and 2011 [26].
Flow cytometry
Expression of peptide specific T cell receptor (TCR) was
examined by FACS-CantoII (Becton Dickinson, San Jose,
CA) using KIF20A-66/HLA-A*2402 dextramer-PE (KI
F20A-dextramer) according to the manufacturer’s in-
struction (Immudex, Copenhagen, Denmark). HIV-A24
epitope peptide (RYLRDQQLL)/MHC-dextramer (HIV-
dextramer) was used as negative control. Briefly, cells
were incubated with peptide-HLA-A*2402 dextramer-PE
for 10 minutes at room temperature, then treated with
FITC-conjugated anti-human CD8 monoclonal antibody
(mAb), APC-conjugated anti-human CD3 mAb, PE-
Cy7-conjugated anti-human CD4 mAb, and 7-AAD
(BD Biosciences, San Jose, CA) at 4°C for 20 minutes.
Analysis gate was set on the staining profiles using
HIV-dextramer, and positive cell percentage (dextramer+
cells/CD3+ CD4- CD8+ cells) was calculated by subtracting
the percentage of HIV-dextramer+ from that of KIF20A-
dextramer+.
Statistical analysis
StatView version 5.0 (SAS Institute Japan Ltd., Japan)
was used for statistical analysis. TTP and OS curves
were estimated using the Kaplan-Meier methodology
and analyzed with a log-rank test. Mann–Whitney U
test and Chi-square test were used to compare patient
characteristics.
Results
The peptide vaccine treatment
A total of 31 patients with chemotherapy-refractory
pancreatic cancer were enrolled in this trial. 16 patientshad unresectable tumor and 15 had recurrent one after
surgery. Tables 1 and 2 indicate clinicopathological
information of the 31 patients, as well as the patients
in control group, who received best supportive care in
our and other hospitals (Table 1). The peptide in the
amount of either 1.0 mg or 3.0 mg per body was examined
in this phase I/II study. These dosages were well tolerated
in the 31 patients with advanced pancreatic cancer. There
is no severe adverse event (SAE) related to the peptide
vaccine in the 1.0 mg/body-injected group, except the
immunological response at injection sites. As well, no
SAE was observed in the first 6 patients in the 3.0 mg/
body-injected group during the first cycle in the treatment.
Hence, we determined that 3.0 mg per body is an
appropriate dose for phase II part in this study.
Immunological injection site reactions (ISRs) of all
the 31 patients were evaluated. Clinical responses of 29
patients out of 31, who received at least one treatment
cycle (4 injections), were evaluated by immuno-monitor-
ing. ISRs, including adverse reactions on the skin in grades
1–3, was observed in 23 patients out of 29. It should be
noted that there were two patients who were incompatible
with further vaccination treatment due to the exclusion
criteria, such as autoimmune hepatitis and interstitial
pneumonia. The patient, who experienced grade 3
autoimmune hepatitis after 11 months of vaccination,
was recovered after drug withdrawal. Another patient
with the interstitial pneumonia was well recovered by
hospital treatment without any steroid therapy. In these
cases, we could not rule out the possibility whether
these adverse events were related to vaccine treatments
or not.
Clinical outcomes of eligible patients
Among the 29 patients examined in this trial, 21 patients
yielded the status of “stable disease” (SD), while 8 resulted
in “progressive disease” (PD) after one cycle of the
treatment (injections of the peptide vaccine for 4 times)
(Table 2). The rate of disease control at the time of one
cycle was calculated to be 72%. 8 patients showed
objective tumor response at target lesions (Figure 1).
On the other hand, according to RECIST criteria, the
other patients were not classified as partial response
(PR), since the ratio of tumor shrinkage was insufficient.
One patient (case 9) achieved “complete response” (CR)
after SD over the long term (Table 2, Figures 1a, 2, and 3).
The rate of objective response to the total was calculated
to be 25.8%.
Case 9 describes a 33-year-old female ended up with
CR after 25 months including a long period of SD
(Figure 1a). This patient underwent pancreatoduode-
nectomy in November 2008 and was diagnosed with
giant cell pancreatic cancer. Adjuvant chemotherapy
utilizing gemcitabine was discontinued at the one course
Table 1 Clinical status and profile of the patients
KIF20A peptide vaccine treatment Best supportive care
Chiba (n = 31) * Chiba (n = 9) * Multi-center (n = 81) **
Age (average, (range)) 61.3 (33–80) 64 (53–82) 64.5 (41–85)
Sex (Male: Female) 17:14 5:4 49:32
Performance status (0:1:2:3) 11:8:12:0 1:3:3:2 13:28:36:0 ***
Status of primary lesion (Resected: Unresected) 15:16 1:8 23:58
Median survival time (days) 142.0 ± 23.7 83.0 ± 33.5 62.0 ± 6.5
Mean survival time (days) 171.8 ± 23.8 93.3 ± 14.8 91.1 ± 11.6
*, Clinical data obtained at our institution, Chiba Tokushukai Hospital.
**, Clinical data of Multi-center (n = 81) include those obtained from Chiba and other three hospitals.
***, 4 cases were excluded, since Performance Status was not determined.
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including hematopoietic toxicity. In February 2009,
a progressive solitary liver metastasis was diagnosed
(Figure 1a). There was no clinical sign of inflammation
at the time of April 13th, 2009. White blood cell count
(2.8 × 103/µ-l) and CRP level (0.02 mg/dl) were
within normal limits. Vaccination started on April 23rd,
2009, and the tumor kept stable condition during the
administration. After 8 months, shrinkage of the tumor
size was observed. Vaccination was discontinued after
11 months, because the level of liver enzyme was increased
and thus autoimmune hepatitis was suspected. None-
theless, the tumor continued to shrink and became
undetectable by CT 25 months after the start of
administration. At the time of the submission of this
manuscript, there is no sign of relapse or metastasis,
and the general condition of the patient has been kept
well with the performance status (PS) of zero.
Case 14 reports a 60-year-old male who showed object-
ive response (Figure 1b). After pancreatoduodenectomy,
gemcitabine treatment started in October 2008 and liver
metastasis was found 3 months later. Followed by TS-1
chemotherapy, we found that metastatic lesions in the
liver progressed after the condition of SD during 3 cycles
of TS-1 treatment. After 1 cycle of the peptide vaccine,
one target lesion of liver metastases located at S8 was
shrunken. This lesion kept shrinking until September
2009, and became hardly detectable by CT scan. Similarly,
a metastatic lesion in the lymph node was significantly
shrunken until September 2009. However, the other
target lesion (S4) in the liver showed no response to
the vaccine treatment and the tumor progression was
promoted after 2 cycles. Finally, the patient died at
220 days after the start of the vaccination.
In case 24, a 74-year-old male also showed objective
response (Figure 1c). After distal pancreatectomy in
August 2007, adjuvant chemotherapy utilizing gemcitabine
was performed for 6 months and then switched to TS-1
because of the side effect. Bone metastasis was found in
the xiphoid process by CT scan in April 2009. Radiationtherapy was performed to the xiphoid process in May
2009, but the tumor did not respond well. The patient
was enrolled into the peptide vaccine trial in July 2009
after one month of cooling off period. Bone metastasis
started to shrink after one cycle of the peptide vaccine
treatment. The precordial pain was rapidly diminished
and well controlled without opioid treatment. After the
5th shot of the peptide, Grade 3 interstitial pneumonia
was observed and the treatment was discontinued. The
patient was hospitalized in one week of treatment without
any steroid therapy and then well recovered. Even without
the vaccination, pain was well controlled and tumor
markers kept decreasing for the next two months.
After the re-progression of the disease, gemcitabine
was administered and no clinical effect was observed.
Since the patient desired to receive the peptide vaccine
again, we obtained an approval of the re-entry of this
case from the Ethical committee. The vaccine treat-
ment was restarted with careful monitoring, while
neither adverse events nor clinical effect was observed
in this second round of drug administration. His overall
survival period from the first day of administration was
495 days.
The median overall survival time of 31 patients was
142 days, and the progression free survival period was
56 days (Figures 4a and 4b). In comparison with the
control group without the vaccine treatment, who are
the patients visited Chiba Tokushukai Hospital in the
period between January 2007 and January 2009 (MST:
83 days), overall survival of the patients with the
KIF20A-peptide vaccination was statistically significant
(p = 0.0468, MST: 142 vs. 83 days) (Figure 4c). Moreover,
MST of the patients who received BSC was 63 days.
Compared to the control group in multi-center, Overall
Survival of the vaccinated patients was significantly
improved (p = 0.0020, MST: 142 vs. 63 days) (Figure 4c).
Taken together, we concluded that the cancer vac-
cination utilizing KIF20A-derived peptide was signifi-
cantly effective as immunotherapy against advanced
pancreatic cancer.
Table 2 Patient characteristics and clinical responses












1 75 M Local LNs 1 4 PD 0 N.A. +
2 57 F Local 1 11 PD 1 ++ ++
3 72 M Liver 1 3 - 0 N.T. N.T.
4 60 M Lung, local LNs 1 19 SD Yes Lung metastasis 2 + -
5 72 F Primary , liver 1 12 PD 1 + +++
6 65 F Liver 1 4 PD 0 + +
7 61 F Local , liver 3 14 SD 2 + +++
8 57 F Primary, liver 3 10 SD 2 ++ +++
9 33 F Paraaortic LNs 3 29 SD Yes(CR) Liver metastasis 3 N.A. +++
10 76 M Liver 3 12 PD 2 - ++
11 55 F Primary, lung 3 17 SD 1 + -
12 58 M Primary 3 5 PD 0 - -
13 58 F Live, lung, LNs 3 10 SD 1 - ++
14 60 M Liver, LNs 3 17 SD Yes Liver metastasis, LNs 2 +++ +++
15 80 F Liver, LNs, lung 3 5 PD 0 - +
16 58 M Primary, liver, lung 3 13 PD 1 - ++
17 49 M Parimary 3 17 SD 2 + +++
18 62 M Primary, liver, LNs 3 7 SD 1 - +++
19 61 M Primarym, liver, lung, LNs 3 11 SD 2 - +
20 58 M LNs, lung 3 25 SD 2 + +++
21 47 M Primary, liver 3 13 SD 1 - +
22 71 F Liver, local LNs 3 7 SD Yes Liver metastasis 2 N.A. ++
23 50 M Local, LNs 3 6 SD 0 N.A. -
24 74 M Bone 3 21 SD Yes Bone metastasis 2 N.A. +++
25 69 F Primary 3 2 - 0 N.T. N.T.
26 80 M Liver, lung 3 18 SD 1 + +++
27 44 M Liver, lung, local LNs 3 24 SD Yes Lung and liver metastasis 1 + -
28 61 F Peritoneal, local LNs 3 9 SD Yes Peritoneal metastasis 0 - -
29 46 M Liver 3 10 SD 2 - +++
30 64 F Liver 3 9 SD 2 - +++


















No. PFS(day) OS (day) Pre-vaccination Post-vaccination
WBC(/mm3) Lymphocyte (%) Lymphocyte (/mm3) WBC(/mm3) Lymphocyte (%) Lymphocyte (/mm3)
1 36 36 7300 7 511 5300 10.5 557
2 26 108 7400 13 962 7900 8 632
3 31 31 7800 11 858 16200 10.5 1701
4 223 283 5100 21 1071 5200 10.5 546
5 24 128 2400 25.5 612 4200 10.8 454
6 26 40 4500 16.5 743 8000 4.1 328
7 55 155 4000 25 1000 6400 18.3 1171
8 56 145 4500 33 1485 14100 16 2256
9 >1219 >1219 2500 44.5 1113 3600 33 1188
10 27 142 2300 29.5 679 5800 11.5 667
11 112 225 2600 9 234 2200 11.5 253
12 32 32 4500 30 1350 2400 10.7 257
13 57 97 7100 15.5 1101 9100 10.5 956
14 169 220 2300 27 621 4100 19.5 800
15 24 44 8500 9.5 808 13300 4.8 638
16 28 182 4800 27 1296 6400 19.3 1235
17 169 309 6200 26.5 1643 7900 17.5 1383
18 93 93 4200 28 1176 6600 18.6 1228
19 57 105 10200 20.5 2091 28700 9 2583
20 169 332 10100 34 3434 7600 19.5 1482
21 56 249 6000 27.5 1650 9600 8 768
22 89 89 7000 11.5 805 5200 20 1040
23 148 148 7900 20 1580 11200 19 2128
24 415 495 3800 16 608 5600 17.8 997
25 11 11 7600 21.5 1634 7400 20.5 1517
26 112 207 6600 24 1584 7500 21.5 1613
27 115 317 2900 23.5 682 4000 25.5 1020
28 69 69 9000 26.5 2385 11200 7.5 840
29 52 388 4000 26 1040 5600 24.6 1378
30 56 69 4800 26.5 1272 8900 7.1 632
31 56 82 6800 33 2244 8300 19.5 1619
*Clinical response was evaluated one month after vaccination. PD, Progressive disease; SD, Stable disease; CR, Complete response; OR, Objective response.
**Best CTL response after vaccination. CTL responses were evaluated and classified based on the algorithm as described in Methods.
N.T. (Not Tested); CTL response was not tested in the samples in which PD was observed within one course of the treatment.
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Figure 1 CT images of the target lesions showing objective tumor response. Representative CT images of the target lesions were shown,
such as liver metastasis in case 9 (a), liver metastasis in case 14 (b), bone metastasis in xiphoid process in case 24 (c), liver metastasis in case 22
(d), liver metastasis in case 27 (e), peritoneal metastasis in case 28 (f), and liver metastasis in case 31 (g). Arrow head indicates the target lesion.
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We expected that the number of CTL responded to
KIF20A peptide may be associated with the efficacy of
the vaccine treatment. Therefore, CTL response wasmeasured by ELISPOT assay in 29 patients who received
the vaccination at least one cycle (Table 2). Among them,
CTL responses in 24 patients were comparable in pre-
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Figure 2 Peptide specific CTL response in case 9. Strong CTL responses specific to KIF20A-66 peptide were obtained at the time of 2 months
after vaccination. The responses were kept strong positive during 2 years of the observation period. The number of the spots specific to peptide
was calculated by subtracting the spot number in control wells from that in peptide-pulsed TISI cells.
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determined by the algorithm flow chart [25]. Of note, strong
CTL response specific to KIF20A-66 was observed two
months after the start of the vaccination in the patient of
case 9, who achieved CR. This response kept strong for one
year, and it was detectable even 2 years after the drug was
discontinued (Figure 2). A flow cytometry assay demon-
strated that the number of KIF20A-66 specific TCR in CD8-
positive T cells was consistent with the grades classified
according to our algorithm flow chart [25] (Figure 3a), com-
pared to the negative control stain utilizing HIV-dextramer
(Figure 3b). Also, injection site reactions were observed in 23
patients. MST of the patients with positive skin reaction was
182 days, while that of the patients with negative reaction
was 42 days (Figure 5). These results demonstrate that CTL
response and ISRs could be employed as biological markers
to rapidly diagnose the efficacy of the peptide vaccination.
Consistent with these results, when the 29 patients were clas-
sified into two groups in regard to the content ratio of
lymphocyte (more than 16% (n = 23) vs. less than 16%
(n = 6)), the group with higher number of lymphocyte yielded
better prognosis with statistical significance (p = 0.0296). Thisresult suggests that the number of lymphocyte is positively
associated with the survival of the patients.Discussion
Currently, there is no therapeutic strategy effective for the
patients, whose pancreatic cancer is refractory to gemcita-
bine and TS-1. Combination therapy utilizing a couple of
cytotoxic agents with gemcitabine has been investigated,
but it has been failed to prove their clinical benefit so far
[6-15]. We conducted an expression screening of proteins
that were highly up-regulated in tumor cells, and not in
normal cells, as a candidate of the target to develop novel
anti-cancer drugs [20]. We successfully identified a
member of kinesin super family protein 20A (KIF20A).
Subsequently, we established an epitope peptide that were
likely to be presented as an antigen in a HLA-A*2402- or
HLA-A*0201-restricted manner [23,24,27]. In this report,
we demonstrated that the KIF20A-derived peptide could
improve the prognosis of the patients with advanced pan-
creatic cancer, suggesting that the KIF20A peptide vaccin-
ation is a promising approach as cancer immunotherapy.
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Figure 3 Flow cytometry analysis of KIF20A-66 specific TCR expression in CD8+ cells in case 9. Cells were stained with either KIF20A-
dextramer (a) or HIV-dextramer (b) after IVS as described in Methods section. The content rates of KIF20A-dextramer positive or HIV-dextramer
positive cells (red dots) in CD3+ CD4- CD8+ cells are shown above panels in red.
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KIF20A-66 peptide vaccine monotherapy for the patients
with HLA-A*2402. This vaccine was well tolerated in the
doses of 1.0 mg and 3.0 mg/body, although we do not ex-
clude the possibility of two adverse events related to vaccin-
ation. The MST of 31 patients was 142 days in this phase I/
II trial, indicating that vaccine treatment utilizing KIF20A-66
peptide provides survival benefit. Therefore, we concluded
that the peptide vaccination improved overall survival period
of the patients with advanced pancreatic cancer, who wereresistant to chemotherapy. A placebo-controlled clinical trial
should be required to further establish this peptide vaccine
as a standard immunotherapy against pancreatic cancer.
We realized, during the course of peptide vaccination,
that an induction of peptide-specific CTL and positive skin
reaction were observed in the majority of the patients. We
assure that these reactions could be employed as bio-
markers of preferable clinical responses. Therefore, the
number of CTL induced by peptide injection and the skin
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Figure 4 (See legend on next page.)
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Figure 4 Overall survival and progression free survival in phase I/II trial. Overall survival of the patients was shown in Kaplan-Meier plots
(n = 31) (a). MST of the patients with peptide vaccine was 142 days. PFS of the patients with peptide vaccine was 56 days (b). In comparison with
the control patients who were treated with best supportive care in Chiba Tokushukai Hospital (n = 9), overall survival of the patients with the
KIF20A-peptide vaccination was fairly improved (p = 0.0468, MST: 142 vs. 83 days). In comparison with the BSC patients (n = 81), overall survival of
the vaccinated patients in Chiba Tokushukai Hospital was significantly improved (p = 0.0020, MST: 142 vs. 63 days) (c).
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resulted in CR in case 9. The liver metastasis continuously
shrunk even after the peptide vaccination was discontinued
(Figure 1a), and there was no sign of recurrence or me-
tastasis at the time of 40 months after the vaccination
started. Since biopsy of the tumor lesion was not per-
formed during or after the vaccination, there is no infor-
mation regarding the tumor infiltrating lymphocyte
(TIL). This example indicates that positive correlation
between tumor shrinkage and immunological reactions
is of clinically interest (Figure 2). On the other hand,
there is no CTL induction detected in Case No. 4, 27,
and 28, while objective shrinkages were observed in
these patients during the course of treatment. Since the
number of CTL is usually low in peripheral blood, the
CTL induction is measured after the stimulation utiliz-
ing respective peptide and IL-2 to yield higher detection
limit. Despite this procedure, it is assumed that the inten-
sity of CTL induction and the efficacy of vaccine treat-
ment are not necessarily correlated according to a linear
function, possibly due to the high expression levels of
MHC Class I and/or targeted antigen KIF20A in tumor
cells. Therefore, development of sensitive and reliable
methods to detect CTL is required to evaluate the results
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Figure 5 Correlation between OS and ISR. The local immune reactions a
patients who had injection site reaction was 182 days, while MST of the paThe US FDA published the guidance for the therapeutic
cancer vaccine [28], describing that it is hard to expect
clinical benefit of the vaccine treatment for the patients
after multiple chemotherapy regimens due to very poor
immune status. However, unlike many trials tested so
far utilizing other peptide vaccines, this clinical study
was quite successful. Our results clearly demonstrate
that therapeutic cancer vaccination is still a promising
approach for advanced pancreatic cancer after the failure
of standard chemotherapy. In general, patients with
relapsed or recurrent metastatic disease receive multiple
treatments for their cancer. These therapies may be
detrimental to the immune system, and adequate time
is required for the cancer vaccine to elicit a detectable
immune response. Given such therapeutic conditions
affect the results of peptide vaccination, the use of
adjuvant setting and the cohort study during an early
treatment of the vaccine may be necessary to better
understand a cause-and-result relationship of cancer
immunotherapy. Furthermore, it is important to develop
the peptides with the higher immunogenicity against
active oncoproteins. Indeed, we have examined several
peptides derived from a variety of cancer-testis antigens
that have the oncogenic activity, including KIF20A,
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t the site of injection were observed in 23 patients. MST of the
tients without such reaction (n = 6) was 42 days (p < 0.0001).
Asahara et al. Journal of Translational Medicine 2013, 11:291 Page 12 of 13
http://www.translational-medicine.com/content/11/1/291CDCA1, RNF43, and TOMM34 [16,17,20,22-25,27,29].
We propose that the trial of the cocktail vaccine of
these high immunogenic peptides including KIF20A-66
will provide with better treatment and cure for cancer.
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